183 related articles for article (PubMed ID: 23678002)
1. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.
Xia Y; Yang W; Bu W; Ji H; Zhao X; Zheng Y; Lin X; Li Y; Lu Z
J Biol Chem; 2013 Jul; 288(27):19321-9. PubMed ID: 23678002
[TBL] [Abstract][Full Text] [Related]
2. miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun signaling pathway in colorectal cancer.
Sui H; Cai GX; Pan SF; Deng WL; Wang YW; Chen ZS; Cai SJ; Zhu HR; Li Q
Mol Cancer Ther; 2014 Dec; 13(12):3137-51. PubMed ID: 25205654
[TBL] [Abstract][Full Text] [Related]
3. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
[TBL] [Abstract][Full Text] [Related]
4. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis.
Liu J; Minemoto Y; Lin A
Mol Cell Biol; 2004 Dec; 24(24):10844-56. PubMed ID: 15572687
[TBL] [Abstract][Full Text] [Related]
5. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium.
Gao X; Wu X; Yan J; Zhang J; Zhao W; DeMarco D; Zhang Y; Bakhos M; Mignery G; Sun J; Li Z; Fill M; Ai X
Cardiovasc Res; 2018 Apr; 114(5):737-746. PubMed ID: 29360953
[TBL] [Abstract][Full Text] [Related]
7. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
[TBL] [Abstract][Full Text] [Related]
8. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
9. C-Jun N-terminal kinase signalling pathway in response to cisplatin.
Yan D; An G; Kuo MT
J Cell Mol Med; 2016 Nov; 20(11):2013-2019. PubMed ID: 27374471
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
[TBL] [Abstract][Full Text] [Related]
11. Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network.
Ahmed SU; Milner J
PLoS One; 2009 Oct; 4(10):e7305. PubMed ID: 19806201
[TBL] [Abstract][Full Text] [Related]
12. Isoform-specific functions of c-Jun N-terminal kinase 1 and 2 in lung ischemia-reperfusion injury through the c-Jun/activator protein-1 pathway.
Tan J; Gao W; Yang W; Zeng X; Wang L; Cui X
J Thorac Cardiovasc Surg; 2021 Aug; 162(2):e143-e156. PubMed ID: 32414595
[TBL] [Abstract][Full Text] [Related]
13. Differential transmission of MEKK1 morphogenetic signals by JNK1 and JNK2.
Takatori A; Geh E; Chen L; Zhang L; Meller J; Xia Y
Development; 2008 Jan; 135(1):23-32. PubMed ID: 18032450
[TBL] [Abstract][Full Text] [Related]
14. Lack of c-Jun activity increases survival to cisplatin.
Sánchez-Pérez I; Perona R
FEBS Lett; 1999 Jun; 453(1-2):151-8. PubMed ID: 10403393
[TBL] [Abstract][Full Text] [Related]
15. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
Filomeni G; Turella P; Dupuis ML; Forini O; Ciriolo MR; Cianfriglia M; Pezzola S; Federici G; Caccuri AM
Mol Cancer Ther; 2008 Feb; 7(2):371-9. PubMed ID: 18281520
[TBL] [Abstract][Full Text] [Related]
16. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
17. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation.
Sabapathy K; Hochedlinger K; Nam SY; Bauer A; Karin M; Wagner EF
Mol Cell; 2004 Sep; 15(5):713-25. PubMed ID: 15350216
[TBL] [Abstract][Full Text] [Related]
18. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
19. CSN6 positively regulates c-Jun in a MEKK1-dependent manner.
Shin J; Phan L; Chen J; Lu Z; Lee MH
Cell Cycle; 2015; 14(19):3079-87. PubMed ID: 26237449
[TBL] [Abstract][Full Text] [Related]
20. A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma.
Lee J; Jiffar T; Kupferman ME
PLoS One; 2012; 7(1):e30246. PubMed ID: 22276165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
